Showing results (161-170 of 315) with videos related to
Sort By:
Pageof 32
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1984
Phase I trial of esorubicin (4'deoxydoxorubicin)H S Garewal, A Robertone, S E Salmon, et al.American Journal of Obstetrics and Gynecology|July 15, 1983
Multiagent chemotherapy in relapsing ovarian cancerE A Surwit, D S Alberts, W Crisp, et al.Cancer Research|September 15, 1988
In vitro rat myocyte cardiotoxicity model for antitumor antibiotics using adenosine triphosphate/protein ratiosR T Dorr, K A Bozak, N G Shipp, et al.The Journal of Antibiotics|February 1, 1981
Cefonicid: a stable beta-lactamase inhibitorR J Mehta, D J Newman, B A Bowie, et al.Gynecologic Oncology|May 1, 1984
Phase II and pharmacokinetic study of high-dose methotrexate in the treatment of advanced gynecologic malignancy. A Southwest Oncology Group TrialR D Hilgers, D S Alberts, J C Standefer, et al.Anti-Cancer Drugs|April 6, 2001
Preclinical antitumor activity of the azonafide series of anthracene-based DNA intercalatorsR T Dorr, J D Liddil, S M Sami, et al.Journal of Pharmaceutical Sciences|May 1, 1978
Hydrolysis and protein binding of melphalanS Y Chang, D S Alberts, D Farquhar, et al.Cancer Research|May 15, 1987
Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trialR F Struck, D S Alberts, K Horne, et al.Journal of Medicinal Chemistry|November 26, 1997
1,4-disubstituted anthracene antitumor agentsB S Iyengar, R T Dorr, D S Alberts, et al.The New England Journal of Medicine|June 15, 1978
Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugsS E Salmon, A W Hamburger, B Soehnlen, et al.Pageof 32